在糖尿病足 (DFU) 中菌体治疗的有效性:一个系统的审查
Amir Hossein Esfandiari1, Zahra Mobarezi1, Samaneh Abolbashari2
1Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
BMC infectious diseases
|July 2, 2025
概括
菌体治疗显示出治疗糖尿病足感染的前景,即使是抗生素耐药的. 需要进一步的大规模研究来确认其有效性并建立临床指南.
科学领域:
- 微生物学与传染病的研究
- 生物技术和治疗学
背景情况:
- 糖尿病足 (DFU) 由多药耐药 (MDR) 细菌感染复杂化,增加截肢风险.
- 菌体 (菌体) 治疗为对抗这些感染提供了一种针对常规抗生素的有针对性的替代方案.
研究的目的:
- 系统地审查菌体治疗在治疗与糖尿病足相关的细菌感染中的疗效.
主要方法:
- 在主要数据库 (PubMed,Scopus,Web of Science,Embase) 进行了系统的文献搜索,直到2024年10月.
- 包括对DFU的菌体治疗的原始英语研究;不包括评论和非英语文章.
- 数据提取和质量评估由两位独立审查员进行.
主要成果:
- 二十一项研究证实了菌体治疗对DFU关键病原体的有效性,如金黄色葡萄球菌和Pseudomonas aeruginosa.
- 菌体尾酒在防止再生和克服抵抗方面表现出比单个菌体更高的疗效.
- 观察到与抗生素的协同效应,改善生物膜透和细菌根除;报告了高耐受性.
结论:
- 菌体疗法是MDR DFU感染的安全和可行的选择,对生物膜特别有效,并与抗生素结合使用.
- 来自小规模研究的有限证据需要进一步研究,包括大型随机对照试验 (RCT).
- 标准化协议,更广泛的菌体尾酒,优化输送和RCT对于临床采用和监管批准至关重要.
相关概念视频
Diabetes: Management and Pharmacotherapy
409
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
409
Lytic Cycle of Bacteriophages
72.2K
Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the...
72.2K


